Browse DSE

Summary
SymbolDSE
Namedermatan sulfate epimerase
Aliases DSEPI; SART2; squamous cell carcinoma antigen recognized by T cells 2; DSEPPI; EDSMC2; SART-2; DS epimerase; ......
Chromosomal Location6q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein
Domain PF16332 Domain of unknown function (DUF4962)
Function

Converts D-glucuronic acid to L-iduronic acid (IdoUA) residues.

> Gene Ontology
 
Biological Process GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006029 proteoglycan metabolic process
GO:0006790 sulfur compound metabolic process
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0015012 heparan sulfate proteoglycan biosynthetic process
GO:0030166 proteoglycan biosynthetic process
GO:0030201 heparan sulfate proteoglycan metabolic process
GO:0030203 glycosaminoglycan metabolic process
GO:0030204 chondroitin sulfate metabolic process
GO:0030205 dermatan sulfate metabolic process
GO:0030206 chondroitin sulfate biosynthetic process
GO:0030208 dermatan sulfate biosynthetic process
GO:0044272 sulfur compound biosynthetic process
GO:0050650 chondroitin sulfate proteoglycan biosynthetic process
GO:0050651 dermatan sulfate proteoglycan biosynthetic process
GO:0050654 chondroitin sulfate proteoglycan metabolic process
GO:0050655 dermatan sulfate proteoglycan metabolic process
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0016853 isomerase activity
GO:0016854 racemase and epimerase activity
GO:0016857 racemase and epimerase activity, acting on carbohydrates and derivatives
GO:0047757 chondroitin-glucuronate 5-epimerase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00532 Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate
hsa01100 Metabolic pathways
Reactome R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-2022923: Dermatan sulfate biosynthesis
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolDSE
Namedermatan sulfate epimerase
Aliases DSEPI; SART2; squamous cell carcinoma antigen recognized by T cells 2; DSEPPI; EDSMC2; SART-2; DS epimerase; ......
Chromosomal Location6q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DSE and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between DSE and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21480325Hepatocellular CarcinomaPromote immunityThe TAAs consisting of cyclophilin B, squamous cell carcinoma antigen recognized by T cells (SART) 2, SART3, p53, multidrug resistance-associated protein (MRP) 3, alpha-fetoprotein (AFP) and human telomerase reverse transcriptase (hTERT) were frequently recognized by T cells and these TAA-derived peptides were capable of generating peptide-specific CTLs in HCC patients, which suggested that these TAAs are immunogenic. Cyclophilin B, SART2, SART3, p53, MRP3, AFP, and hTERT were immunogenic targets for HCC immunotherapy.
Summary
SymbolDSE
Namedermatan sulfate epimerase
Aliases DSEPI; SART2; squamous cell carcinoma antigen recognized by T cells 2; DSEPPI; EDSMC2; SART-2; DS epimerase; ......
Chromosomal Location6q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DSE in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDSE
Namedermatan sulfate epimerase
Aliases DSEPI; SART2; squamous cell carcinoma antigen recognized by T cells 2; DSEPPI; EDSMC2; SART-2; DS epimerase; ......
Chromosomal Location6q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DSE in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2690.562
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6040.658
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0160.987
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2710.453
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.410.853
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0890.976
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0060.989
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0470.974
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0710.966
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5490.652
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1910.512
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2770.0454
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DSE in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.57.43.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.2018.20.274
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614014.3-14.30.209
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDSE
Namedermatan sulfate epimerase
Aliases DSEPI; SART2; squamous cell carcinoma antigen recognized by T cells 2; DSEPPI; EDSMC2; SART-2; DS epimerase; ......
Chromosomal Location6q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DSE. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDSE
Namedermatan sulfate epimerase
Aliases DSEPI; SART2; squamous cell carcinoma antigen recognized by T cells 2; DSEPPI; EDSMC2; SART-2; DS epimerase; ......
Chromosomal Location6q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DSE. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DSE.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDSE
Namedermatan sulfate epimerase
Aliases DSEPI; SART2; squamous cell carcinoma antigen recognized by T cells 2; DSEPPI; EDSMC2; SART-2; DS epimerase; ......
Chromosomal Location6q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DSE. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDSE
Namedermatan sulfate epimerase
Aliases DSEPI; SART2; squamous cell carcinoma antigen recognized by T cells 2; DSEPPI; EDSMC2; SART-2; DS epimerase; ......
Chromosomal Location6q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DSE expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDSE
Namedermatan sulfate epimerase
Aliases DSEPI; SART2; squamous cell carcinoma antigen recognized by T cells 2; DSEPPI; EDSMC2; SART-2; DS epimerase; ......
Chromosomal Location6q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DSE and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDSE
Namedermatan sulfate epimerase
Aliases DSEPI; SART2; squamous cell carcinoma antigen recognized by T cells 2; DSEPPI; EDSMC2; SART-2; DS epimerase; ......
Chromosomal Location6q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DSE collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.